Angle, a developer of circulating tumor cell (CTC) assays, announced on Wednesday a supplier agreement with AstraZeneca to collaborate on developing and validating a method for detecting micronuclei in CTCs using its existing DNA damage response (DDR) assay.
In the initial six-month development phase, Angle is set to earn £150,000 (approximately $186,542). The collaboration will primarily occur at Angle’s Guildford, UK, laboratory. Angle has already crafted a CTC-based assay that gauges the expression of pKAP1, a pivotal protein in the DDR pathway. This partnership aims to further enhance the capabilities of Angle’s DDR assay.
The company anticipates that their DDR assay could play a crucial role in advancing targeted therapies. Moreover, it holds potential for monitoring treatment responses to such therapies. Andrew Newland, CEO of Angle, expressed the company’s ambition to expand its pharmaceutical services division.
Karen Miller, Chief Scientific Officer at Angle, emphasized the importance of minimally invasive, reliable, and replicable DDR assays in light of the growing exploration of DNA damage response/PARP inhibitors, either as standalone treatments or in combination with chemotherapy or immunotherapy.
